Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · IEX Real-Time Price · USD
2.150
-0.010 (-0.46%)
Mar 1, 2024, 4:00 PM EST - Market closed
-0.46%
Market Cap 13.30M
Revenue (ttm) 324,066
Net Income (ttm) -19.13M
Shares Out 6.19M
EPS (ttm) -3.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 79,396
Open 2.180
Previous Close 2.160
Day's Range 2.070 - 2.220
52-Week Range 0.790 - 5.610
Beta 1.34
Analysts Strong Buy
Price Target 27.00 (+1,155.81%)
Earnings Date Apr 1, 2024

About IKT

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development coll... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 23, 2020
Employees 6
Stock Exchange NASDAQ
Ticker Symbol IKT
Full Company Profile

Financial Performance

In 2022, IKT's revenue was $123,440, a decrease of -96.02% compared to the previous year's $3.10 million. Losses were -$18.05 million, 22.1% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for IKT stock is "Strong Buy" and the 12-month stock price forecast is $27.0.

Price Target
$27.0
(1,155.81% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate Company to pursue eleven indications for IkT-001Pro; all previously approved for treat...

4 days ago - GlobeNewsWire

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson's disease - - The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Park...

25 days ago - GlobeNewsWire

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibit...

4 weeks ago - GlobeNewsWire

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-Pr...

6 weeks ago - GlobeNewsWire

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

2 months ago - GlobeNewsWire

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications -

3 months ago - GlobeNewsWire

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET

3 months ago - GlobeNewsWire

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" r...

4 months ago - GlobeNewsWire

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

4 months ago - GlobeNewsWire

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

5 months ago - GlobeNewsWire

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

- New tablet formulation of risvodetinib approximately doubles drug exposure at same dose – - Tablet formulation to be evaluated in the planned 12-month extension portion of the 201 trial– BOSTON and ...

6 months ago - PRNewsWire

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

BOSTON and ATLANTA , Aug. 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

6 months ago - PRNewsWire

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

- Company to assess new molecules arising from internal discovery and other companies to enhance suppression of neurodegeneration through c-Abl inhibition – - Selected non-proprietary name risvodetini...

6 months ago - PRNewsWire

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

- 600 mg IkT-001Pro demonstrated bioequivalence to Standard-of-Care 400 mg Dose of Imatinib mesylate - - Minimal adverse events with consistent drug delivery seen across 31 subjects in the pivotal tri...

7 months ago - PRNewsWire

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Tuesday, August 15, 2023 at 8:00 a.m. ET BOSTON and ATLANTA , Aug. 14, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a cl...

7 months ago - PRNewsWire

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

BOSTON and ATLANTA , Aug. 7, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

7 months ago - PRNewsWire

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON and ATLANTA , July 17, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor ther...

8 months ago - PRNewsWire

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor thera...

8 months ago - PRNewsWire

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

- 600 mg dose of IkT-001Pro selected as the bioequivalent dose relative to standard of care 400 mg imatinib mesylate - - On-track to complete pivotal clinical phase of the 501 study by the end of 2Q22...

9 months ago - PRNewsWire

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

- Company to highlight the '201' trial at multiple regional seminars for physicians - - Up to 61% of clinical sites actively screening patients by close of 2Q23 - BOSTON and ATLANTA , June 21, 2023 /P...

9 months ago - PRNewsWire

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

BOSTON and ATLANTA , May 30, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

9 months ago - PRNewsWire

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

BOSTON and ATLANTA , May 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Park...

10 months ago - PRNewsWire

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Tuesday, May 16, 2023 at 8:00 a.m. ET BOSTON and ATLANTA , May 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinic...

10 months ago - PRNewsWire

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor th...

10 months ago - PRNewsWire

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

BOSTON and ATLANTA , May 4, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor th...

10 months ago - PRNewsWire